Patients are eligible with histologically confirmed R/M HNSCC (oral cavity, oropharynx, hypopharynx, or larynx) that has progressed during or after treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 monotherapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.